A Study of WVT078 in Patients With Multiple Myeloma (MM)
Summary
Third Opinion Trial Synopsis:
Doctors are doing a study to figure out how much medicine is safe to use by itself and with another medicine for people with a type of cancer called Multiple Myeloma. They want to find out what amount of the medicine won't make people sick.
Doctors are doing a study to figure out how much medicine is safe to use by itself and with another medicine for people with a type of cancer called Multiple Myeloma. They want to find out what amount of the medicine won't make people sick.
*Third Opinion AI Generated Synopsis
Trial Summary
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
